Logo

Pfizer Receives EU Approval for Xeljanz (tofacitinib citrate- JAK3i) for Moderate to Severe UC Patients

Share this

Pfizer Receives EU Approval for Xeljanz (tofacitinib citrate- JAK3i) for Moderate to Severe UC Patients

Shots:

  •   EU has approved intake of Xeljanz 10mg BID for 8 weeks followed by 5mg or 10mg for moderate to active UC in adults
  •   Xeljanz is now approved in three indication including UC- since 2017- in combination with MTX for RA and for active PsA- approved by EU
  •  This approval is based on the data from three pivotal Ph 3 study from OCTAVE (Induction 1 & 2 and Sustain)

     Ref: Pfizer | Image: Fortune

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions